The World Health Organization’s (WHO’s) 2023 Model Lists of Essential Medicines, published in July 2023, features key updates to the tuberculosis (TB) section. These complement current WHO recommendations for shorter treatment of multidrug-/rifampicin-resistant TB (MDR/RR-TB) and newer options to treat drug-susceptible TB in children and adolescents. WHO’s Global Tuberculosis Programme, with inputs from partners, proposed these changes to the EML based on the latest WHO recommendations and the current availability of TB medicines. Read more here.
top of page
Recent Posts
See AllPhumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to...
110
The WHO has released new guidelines for prophylactic TB treatments. Among the updates to the guidelines are adjusted dosage...
90
The TB-CAPT consortium released a new study recently that showed that the new Xpert MTB/XDR testing can provide signigificantly faster...
140
bottom of page
Comments